Director Ronald Osman gets 50,000-share award from Inhibitor Therapeutics (INTI)

Rhea-AI Filing Summary

OSMAN RONALD E reported acquisition or exercise transactions in this Form 4 filing.

Inhibitor Therapeutics, Inc. reported that director and ten percent owner Ronald E. Osman received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the 2014 Equity Incentive Plan, subject to shareholder approval. After this award, reported indirect ownership totals 23,614,985 common shares, consisting of 100,000 shares held by Mr. Osman and the remaining shares held by the Ronald E. Osman Trust III, for which he serves as sole trustee.

Insider Trade Summary

Net Buyer: 50,000 shares

Net Buy 1 txn

Insider OSMAN RONALD E, Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012

Role Director, 10% Owner | 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	50,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 23,614,985 shares (Indirect, See Footnotes)

Footnotes (2)

1. F1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan, subject to shareholder approval.
2. F2. These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III.

Key Figures

Restricted stock grant: 50,000 shares Grant price: $0.0000 per share Shares owned after transaction: 23,614,985 shares +1 more

4 metrics

Restricted stock grant 50,000 shares Common Stock awarded on May 4, 2026 as compensation

Grant price $0.0000 per share Reported transaction price for the restricted stock award

Shares owned after transaction 23,614,985 shares Indirectly reported holdings of common stock following the award

Direct shares held by Mr. Osman 100,000 shares Portion of total reported holdings owned personally by Ronald E. Osman

Key Terms

restricted common stock, 2014 Equity Incentive Plan, ten percent owner, indirect ownership

4 terms

restricted common stock financial

"Represents restricted common stock issued to the Reporting Person as compensation"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

2014 Equity Incentive Plan financial

"Compensation pursuant to the Issuer's 2014 Equity Incentive Plan, subject to shareholder approval"

ten percent owner financial

"Reporting person is identified in the data as a ten percent owner of the issuer"

indirect ownership financial

"Total shares following transaction are reported with indirect ownership code I"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 01:33 PM Accepted by SEC EDGAR 08/04/2026 - 01:33 PM Learn about SEC filing dates

FAQ

What insider transaction did Inhibitor Therapeutics (INTI) disclose for May 4, 2026?

On May 4, 2026, director and ten percent owner Ronald E. Osman received 50,000 shares of restricted common stock as compensation under the 2014 Equity Incentive Plan, subject to shareholder approval, increasing his reported indirect ownership in Inhibitor Therapeutics.

How many Inhibitor Therapeutics (INTI) shares does Ronald E. Osman own after this grant?

Following the grant, reported indirect ownership totals 23,614,985 common shares. This figure combines 100,000 shares owned by Mr. Osman personally and the remaining shares of common stock held by the Ronald E. Osman Trust III, where he acts as sole trustee.

What kind of shares were granted to Ronald E. Osman in this INTI Form 4 event?

Ronald E. Osman was granted 50,000 shares of restricted common stock as compensation. The award was issued under Inhibitor Therapeutics’ 2014 Equity Incentive Plan and is expressly described as being subject to shareholder approval before becoming fully effective.

How are Ronald E. Osman’s INTI holdings split between him and his trust?

The reported 23,614,985 common shares comprise 100,000 shares owned by Mr. Osman and the balance held by The Ronald E. Osman Trust III. Mr. Osman serves as sole trustee of the trust, which holds the remaining Inhibitor Therapeutics shares.

Was the 50,000-share INTI grant to Ronald E. Osman made under a Rule 10b5-1 plan?

The transaction is reported as a grant or award of restricted stock for compensation, and the Rule 10b5-1 trading plan checkbox is not marked as applicable, indicating it is not designated as executed under a Rule 10b5-1 plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OSMAN RONALD E

(Last) (First) (Middle)

241 AQUAMSI ST

(Street)

CAPE GIRARDEAU MISSOURI 63703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc. [ INTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		50,000(1)	A	$0	23,614,985	I(2)	See Footnotes

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

OSMAN RONALD E

(Last) (First) (Middle)

241 AQUAMSI ST

(Street)

CAPE GIRARDEAU MISSOURI 63703

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012

(Last) (First) (Middle)

241 AQUAMSI ST

(Street)

CAPE GIRARDEAU MISSOURI 63703

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan, subject to shareholder approval.

2. These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III.

	/s/ Ronald E. Osman	08/04/2026
	/s/ Ronald E. Osman trustee of the Ronald E. Osman Trust III	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)